TNX-102 SL

Phase 3Terminated

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

PTSD

Conditions

PTSD

Trial Timeline

Jun 20, 2017 → Jul 27, 2018

NCT ID

NCT03110575

About TNX-102 SL

TNX-102 SL is a phase 3 stage product being developed by Tonix Pharmaceuticals for PTSD. The current trial status is terminated. This product is registered under clinical trial identifier NCT03110575. Target conditions include PTSD.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07464535	Phase 1	Completed	Mar 18, 2022	Apr 30, 2022	Healthy Subjects (HS)
NCT04164719	Phase 1	Completed	Oct 14, 2019	Dec 24, 2019	Healthy Subjects
NCT03110575	Phase 3	Terminated	Jun 20, 2017	Jul 27, 2018	PTSD
NCT02421679	Phase 2	Completed	Apr 14, 2015	May 26, 2016	PTSD
NCT02015234	Phase 3	Completed	Dec 1, 2013	Aug 1, 2015	Primary Fibromyalgia

Competing Products

11 competing products in PTSD

See all competitors

Product	Company	Stage	Hype Score
SYN117 (nepicastat) + Placebo comparator	Johnson & Johnson	Phase 2	52
Quetiapine + Placebo	Johnson & Johnson	Approved	85
Lu AG06466 + Placebo	Lundbeck	Phase 1	30
Mifepristone 1200 mg daily + Placebo	Corcept Therapeutics	Phase 2	47
TNX-102 SL	Tonix Pharmaceuticals	Phase 2	44
TNX-102 SL 5.6 mg	Tonix Pharmaceuticals	Phase 3	69
TNX-102 SL + Placebo	Tonix Pharmaceuticals	Phase 2	44
TNX-102 SL + Placebo SL Tablet	Tonix Pharmaceuticals	Phase 3	69
TNX-102 SL + Placebo	Tonix Pharmaceuticals	Phase 2	44
TNX-102 SL + Placebo SL Tablets	Tonix Pharmaceuticals	Phase 3	69
Ganaxolone + Placebo	Brain Biotech	Phase 2	44

Other Products from Tonix Pharmaceuticals

TNX-102 SLPhase 3

TNX-102 SL 5.6 mgPhase 3

TNX-102 SL Tablet, 2.8 mg + Placebo SL TabletPhase 3

TNX-102 SL Tablet, 2.8mg + Placebo SL TabletPhase 3

TNX-102 SL + Placebo SL TabletPhase 3